Jonathan F. Lovell, Ph.D.

Recombinant protein vaccines, like the Novavax vaccine used to fight COVID-19, offer several advantages over conventional vaccines.

They’re easy to precisely produce. They’re safe, and potentially more effective. And they could require smaller doses.

Because of these traits, there is much interest in developing recombinant influenza vaccines. To date, however, the Food and Drug Administration has approved only one such vaccine.

A University at Buffalo-led research team hopes to add to that number. It is developing a new recombinant flu vaccine – described in a study published today in the journal Cell Reports Medicine – that has the potential to compete with existing vaccines… Continue reading.

WASHINGTON, D.C. — The American Institute for Medical and Biological Engineering (AIMBE) has announced the induction of Jonathan F. Lovell, Ph.D., SUNY Empire Innovation Professor at the University at Buffalo to its College of Fellows.

Election to the AIMBE College of Fellows is among the highest professional distinctions accorded to a medical and biological engineer. The College of Fellows is comprised of the top two percent of medical and biological engineers. College membership honors those who have made outstanding contributions to “engineering and medicine research, practice, or education” and to “the pioneering of new and developing fields of technology, making major advancements in traditional fields of medical and biological engineering or developing/implementing innovative approaches to bioengineering education… Continue reading.